vs
ASP Isotopes Inc.（ASPI）与Sight Sciences, Inc.（SGHT）财务数据对比。点击上方公司名可切换其他公司
Sight Sciences, Inc.的季度营收约是ASP Isotopes Inc.的1.2倍（$20.4M vs $16.7M），ASP Isotopes Inc.同比增速更快（1295.7% vs 6.9%），Sight Sciences, Inc.自由现金流更多（$-2.0M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Sight Sciences, Inc.是一家处于商业化阶段的医疗科技企业，专注于开发及商业化青光眼、干眼症等常见眼部疾病的创新治疗产品，提供微创手术设备与非手术护理解决方案，主要服务美国市场的眼科医师及患者。
ASPI vs SGHT — 直观对比
营收规模更大
SGHT
是对方的1.2倍
$16.7M
营收增速更快
ASPI
高出1288.8%
6.9%
自由现金流更多
SGHT
多$45.5M
$-47.4M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $20.4M |
| 净利润 | — | $-4.2M |
| 毛利率 | 12.5% | 87.3% |
| 营业利润率 | — | -18.0% |
| 净利率 | — | -20.4% |
| 营收同比 | 1295.7% | 6.9% |
| 净利润同比 | -586.8% | 64.9% |
| 每股收益（稀释后） | — | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPISGHT
| Q4 25 | $16.7M | $20.4M | ||
| Q3 25 | $4.9M | $19.9M | ||
| Q2 25 | — | $19.6M | ||
| Q1 25 | — | $17.5M | ||
| Q4 24 | — | $19.1M | ||
| Q3 24 | — | $20.2M | ||
| Q2 24 | — | $21.4M | ||
| Q1 24 | — | $19.3M |
净利润ASPISGHT
| Q4 25 | — | $-4.2M | ||
| Q3 25 | $-12.9M | $-8.2M | ||
| Q2 25 | — | $-11.9M | ||
| Q1 25 | — | $-14.2M | ||
| Q4 24 | — | $-11.8M | ||
| Q3 24 | — | $-11.1M | ||
| Q2 24 | — | $-12.3M | ||
| Q1 24 | — | $-16.3M |
毛利率ASPISGHT
| Q4 25 | 12.5% | 87.3% | ||
| Q3 25 | 8.7% | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
营业利润率ASPISGHT
| Q4 25 | — | -18.0% | ||
| Q3 25 | -306.1% | -39.7% | ||
| Q2 25 | — | -59.6% | ||
| Q1 25 | — | -79.2% | ||
| Q4 24 | — | -62.5% | ||
| Q3 24 | — | -55.7% | ||
| Q2 24 | — | -59.2% | ||
| Q1 24 | — | -76.4% |
净利率ASPISGHT
| Q4 25 | — | -20.4% | ||
| Q3 25 | -263.7% | -41.0% | ||
| Q2 25 | — | -61.0% | ||
| Q1 25 | — | -80.8% | ||
| Q4 24 | — | -62.1% | ||
| Q3 24 | — | -54.9% | ||
| Q2 24 | — | -57.7% | ||
| Q1 24 | — | -84.4% |
每股收益（稀释后）ASPISGHT
| Q4 25 | — | $-0.07 | ||
| Q3 25 | $-0.15 | $-0.16 | ||
| Q2 25 | — | $-0.23 | ||
| Q1 25 | — | $-0.28 | ||
| Q4 24 | — | $-0.23 | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | — | $-0.25 | ||
| Q1 24 | — | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $92.0M |
| 总债务越低越好 | $14.4M | $42.4M |
| 股东权益账面价值 | $204.2M | $63.9M |
| 总资产 | $498.0M | $115.3M |
| 负债/权益比越低杠杆越低 | 0.07× | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资ASPISGHT
| Q4 25 | $333.3M | $92.0M | ||
| Q3 25 | $113.9M | $92.4M | ||
| Q2 25 | — | $101.5M | ||
| Q1 25 | — | $108.8M | ||
| Q4 24 | — | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $118.2M | ||
| Q1 24 | — | $127.3M |
总债务ASPISGHT
| Q4 25 | $14.4M | $42.4M | ||
| Q3 25 | $13.9M | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
股东权益ASPISGHT
| Q4 25 | $204.2M | $63.9M | ||
| Q3 25 | $74.1M | $64.3M | ||
| Q2 25 | — | $70.0M | ||
| Q1 25 | — | $77.6M | ||
| Q4 24 | — | $87.5M | ||
| Q3 24 | — | $95.0M | ||
| Q2 24 | — | $101.6M | ||
| Q1 24 | — | $109.2M |
总资产ASPISGHT
| Q4 25 | $498.0M | $115.3M | ||
| Q3 25 | $225.9M | $116.3M | ||
| Q2 25 | — | $122.0M | ||
| Q1 25 | — | $129.7M | ||
| Q4 24 | — | $142.8M | ||
| Q3 24 | — | $143.6M | ||
| Q2 24 | — | $149.7M | ||
| Q1 24 | — | $155.6M |
负债/权益比ASPISGHT
| Q4 25 | 0.07× | 0.66× | ||
| Q3 25 | 0.19× | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-1.8M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $-2.0M |
| 自由现金流率自由现金流/营收 | -284.7% | -9.7% |
| 资本支出强度资本支出/营收 | 57.9% | 0.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPISGHT
| Q4 25 | $-37.8M | $-1.8M | ||
| Q3 25 | $-8.9M | $-8.7M | ||
| Q2 25 | — | $-7.5M | ||
| Q1 25 | — | $-11.6M | ||
| Q4 24 | — | $-3.5M | ||
| Q3 24 | — | $362.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.8M |
自由现金流ASPISGHT
| Q4 25 | $-47.4M | $-2.0M | ||
| Q3 25 | $-12.0M | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
自由现金流率ASPISGHT
| Q4 25 | -284.7% | -9.7% | ||
| Q3 25 | -245.5% | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
资本支出强度ASPISGHT
| Q4 25 | 57.9% | 0.8% | ||
| Q3 25 | 64.4% | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
